Tandem Diabetes Care, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
Tandem Diabetes Care, Inc. (TNDM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $12.43 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-05.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2021-05-05
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2021-03-31 was $12.43M, a 8718.44% increase year-over-year.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2020-12-31 was $324.00K.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2020-09-30 was $25.87M, a 215475.00% increase year-over-year.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2020-06-30 was $1.00K, a 99.98% decline year-over-year.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2020 was $26.34M, a 379.52% increase from fiscal 2019.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2019 was $5.49M, a 89.83% decline from fiscal 2018.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2018 was $54.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 6 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | $12.43M 10-Q · filed 2021-05-05 | $12.76M derived: sum of 2 quarters · filed 2021-05-05 | $38.63M derived: sum of 3 quarters · filed 2021-05-05 | $38.63M derived: sum of 4 quarters · filed 2021-05-05 | |
| 2020-12-31 | $324.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $26.19M derived: sum of 2 quarters · filed 2021-02-24 | $26.19M derived: sum of 3 quarters · filed 2021-02-24 | $26.34M 10-K · filed 2021-02-24 | |
| 2020-09-30 | $25.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $25.87M derived: sum of 2 quarters · filed 2020-11-05 | $26.01M 10-Q · filed 2020-11-05 | $26.01M derived: sum of 4 quarters · filed 2021-05-05 | |
| 2020-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $142.00K 10-Q · filed 2020-07-30 | $142.00K derived: sum of 3 quarters · filed 2021-05-05 | $154.00K derived: sum of 4 quarters · filed 2021-05-05 | |
| 2020-03-31 | $141.00K 10-Q · filed 2021-05-05 | $141.00K derived: sum of 2 quarters · filed 2021-05-05 | $153.00K derived: sum of 3 quarters · filed 2021-05-05 | $4.72M derived: sum of 4 quarters · filed 2021-05-05 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $12.00K derived: sum of 2 quarters · filed 2021-02-24 | $4.58M derived: sum of 3 quarters · filed 2021-02-24 | $5.49M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $4.58M derived: sum of 2 quarters · filed 2020-11-05 | $5.49M 10-Q · filed 2020-11-05 | $5.66M derived: sum of 4 quarters · filed 2020-11-05 | |
| 2019-06-30 | $4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $5.48M 10-Q · filed 2020-07-30 | $5.65M derived: sum of 3 quarters · filed 2020-07-30 | $9.56M derived: sum of 4 quarters · filed 2020-07-30 | |
| 2019-03-31 | $910.00K 10-Q · filed 2020-04-30 | $1.08M derived: sum of 2 quarters · filed 2020-04-30 | $4.99M derived: sum of 3 quarters · filed 2020-04-30 | $53.31M derived: sum of 4 quarters · filed 2020-04-30 | |
| 2018-12-31 | $169.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $4.08M derived: sum of 2 quarters · filed 2020-02-24 | $52.40M derived: sum of 3 quarters · filed 2020-02-24 | $54.00M 10-K · filed 2020-02-24 | |
| 2018-09-30 | $3.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $52.23M derived: sum of 2 quarters · filed 2019-11-04 | $53.83M 10-Q · filed 2019-11-04 | ||
| 2018-06-30 | $48.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $49.92M 10-Q · filed 2019-08-01 | $49.92M 10-Q · filed 2018-07-30 | ||
| 2018-03-31 | $1.60M 10-Q · filed 2019-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |